Lamivudine
FDA-approved product (tablet, oral), marketed as Epivir, Epivir-Hbv, Lamivudine.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic hepatitis B virus infection
- Hepatitis
- Hepatitis B virus infection
- HIV infection
- HIV-1 infection
- Immunodeficiency disease
- Infection
- Inflammation
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Nucleoside and nucleotide reverse transcriptase inhibitors
- FDA pharmacologic class
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF05; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Lamivudine, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lamivudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
NCT00140725 · start 2000-04
Registered record
- Registry ID
- NCT00140725
- Conditions
- Chronic Hepatitis B
- Interventions
- Lamivudine plus Polyethylene glyco-interferon alfa-2b; Lamivudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2000-04
- Completion
- Not recorded
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis BInterventionLamivudine plus Polyethylene glyco-interferon alfa-2b; LamivudinePhasePhase 3Registry statusCompletedA Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
NCT00002183
Registered record
- Registry ID
- NCT00002183
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate; Amprenavir; Lamivudine; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAbacavir sulfate; Amprenavir; Lamivudine; ZidovudinePhasePhase 1Registry statusCompletedA Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
NCT00002217
Registered record
- Registry ID
- NCT00002217
- Conditions
- HIV Infections
- Interventions
- Lamivudine/Zidovudine; Abacavir sulfate; Amprenavir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionLamivudine/Zidovudine; Abacavir sulfate; AmprenavirPhaseNot applicableRegistry statusCompletedChanging to Nonprotease Inhibitor Treatment to Improve Side Effects
NCT00021463
Registered record
- Registry ID
- NCT00021463
- Conditions
- HIV Infections; Lipodystrophy
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 342
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; LipodystrophyInterventionAbacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; NevirapinePhasePhase 2Registry statusCompletedAn Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
NCT00124241
Registered record
- Registry ID
- NCT00124241
- Conditions
- Hepatitis B
- Interventions
- telbivudine; lamivudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2005-11
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis BInterventiontelbivudine; lamivudinePhasePhase 2Registry statusCompleted